NCI Seeks New Technologies

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 10
Volume 7
Issue 10

BETHESDA, Md--The National Cancer Institute (NCI) is seeking technology systems to revolutionize cancer detection, diagnosis, and treatment. Under a new $48 million, 5-year program dubbed the Unconventional Innovations Program, NCI is looking for new technologies "that will enable sensing of molecular alterations in the body in a way that is highly sensitive and specific, yet nonintrusive."

BETHESDA, Md--The National Cancer Institute (NCI) is seeking technology systems to revolutionize cancer detection, diagnosis, and treatment. Under a new $48 million, 5-year program dubbed the Unconventional Innovations Program, NCI is looking for new technologies "that will enable sensing of molecular alterations in the body in a way that is highly sensitive and specific, yet nonintrusive."

NCI has requested input from molecular and cellular biologists, engineers, physicists, chemists, and computational biologists who can point to new directions for research. Information obtained will be used to outline government research goals that will be issued in late 1998 or early 1999, followed by requests for specific research proposals.

Articles in this issue
Panel Recommends Photofrin for Use in Late-Stage Lung Cancer
California Intervention Raises Consumption of Fruits and Vegetables
ODAC Panel Okays Nolvadex to Reduce Breast Cancer Risk
Evolving Role for Preoperative Chemo in Breast Cancer
NCI Sets Sail on a New Tack In the Stormy Seas of CAM
Opioid Antagonists Can Control Opioid-Induced Constipation
NCI Seeks New Technologies
View Cancer Pain as a ‘Pathogenic Agent’ to be Treated, Expert Says
NIAID Collaborates With VaxGen, Inc. on Trials of AIDSVAX
Clinicians Often Fail To Provide Adequate Genetic Counseling
Networks Assist Community Oncologists in Research Quest
Three Months After Voting Nay, ODAC Backs Valstar Approval
M.D. Anderson Center Will Consolidate Faculty Offices in New Building in 2000
Drug-Seeking Behavior in Pain Patients Rarely Addiction
Device Finds Breast Lesions by Measuring Electropotentials
Recent Videos
4 experts in this video
4 experts in this video
Ongoing research suggests environmental exposures and the role of microbiomes may influence bladder cancer development and response to treatment.
Providing easier access to ancillary services for patients with PDAC who live farther away from the treatment center may help them complete the treatment regimen.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Related Content
EC Approves T-DXd Monotherapy in HR+, HER2-Low/Ultralow Breast Cancer

EC Approves T-DXd Monotherapy in HR+, HER2-Low/Ultralow Breast Cancer

Tim Cortese
April 4th 2025
Article

Results from the phase 3 DESTINY-Breast06 trial demonstrated that T-DXd monotherapy improved PFS over chemotherapy in patients with breast cancer.

Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
April 1st 2025
Podcast

A recent Oncology Decoded podcast focuses on adjuvant therapy like pembrolizumab and optimal post-surgical care for patients with kidney cancer.

All patients identified as low risk for sentinel lymph node positivity with the DecisionDx-Melanoma test had recurrence-free status after 3 years.

DecisionDx-Melanoma Test Accurately Identifies Low-Risk SLN Positivity

Roman Fabbricatore
April 4th 2025
Article

All patients identified as low risk for sentinel lymph node positivity with the DecisionDx-Melanoma test had recurrence-free status after 3 years.

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

Improving NSCLC Surgery Recovery After Climate Disaster Exposure

Leticia Nogueira, PhD, MPH
March 31st 2025
Podcast

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

A futility analysis showed that ociperlimab was unlikely to reach the primary end point of overall survival as part of the phase 3 AdvanTIG-302 trial.

Developers Terminate Clinical Program for Ociperlimab in Lung Cancer

Russ Conroy
April 3rd 2025
Article

A futility analysis showed that ociperlimab was unlikely to reach the primary end point of overall survival as part of the phase 3 AdvanTIG-302 trial.

Data from the phase 3 CheckMate 77T trial support the CHMP’s opinion on approving the perioperative nivolumab regimen for those with resectable NSCLC.

EU’s CHMP Recommends Approving Perioperative Nivolumab Combo in NSCLC

Russ Conroy
April 2nd 2025
Article

Data from the phase 3 CheckMate 77T trial support the CHMP’s opinion on approving the perioperative nivolumab regimen for those with resectable NSCLC.